BACKGROUND & AIMS: While the majority of HCV-infected patients progress to chronic hepatitis, a small fraction of individuals are able to clear the virus. Resolution of infection occurs within the first few weeks to months of infection, suggesting that innate immune functions may be critical for early control. Epidemiologic data support a role for particular NK cell receptor bearing populations in this control, yet the mechanism by which NK cells respond to HCV early in infection is unknown. METHODS: Changes in the phenotype and function of NK cells were investigated in a cohort of 43 individuals identified during various stages of HCV infection with different clinical outcomes. RESULTS: Acute, chronic, and resolved HCV infections were characterized by an expansion of CD56(neg) NK cells. Furthermore, increased levels of HLA-C-binding KIR(+) NK cells were observed in HCV resolvers, while all stages of HCV infection were associated with reduced percentages of NKG2D(+), NKp30(+), and NKp46(+) NK cells, and a slight increase in the ability of NK cells to respond to target cells bearing the ligands for these receptors. In contrast, NKG2A(+) and CD94(+) NK cells were elevated in acute and chronic HCV infection, but not in resolved infection. Most importantly, in acute infection, lower frequencies of NKp30(+), NKp46(+), CD161(+), and NKG2D(+) NK cells were observed in patients who were subsequently able to clear HCV infection than in those becoming chronically infected. CONCLUSIONS: These data implicate particular populations of NK cells in the early control and clearance of HCV infection.
BACKGROUND & AIMS: While the majority of HCV-infectedpatients progress to chronic hepatitis, a small fraction of individuals are able to clear the virus. Resolution of infection occurs within the first few weeks to months of infection, suggesting that innate immune functions may be critical for early control. Epidemiologic data support a role for particular NK cell receptor bearing populations in this control, yet the mechanism by which NK cells respond to HCV early in infection is unknown. METHODS: Changes in the phenotype and function of NK cells were investigated in a cohort of 43 individuals identified during various stages of HCV infection with different clinical outcomes. RESULTS: Acute, chronic, and resolved HCV infections were characterized by an expansion of CD56(neg) NK cells. Furthermore, increased levels of HLA-C-binding KIR(+) NK cells were observed in HCV resolvers, while all stages of HCV infection were associated with reduced percentages of NKG2D(+), NKp30(+), and NKp46(+) NK cells, and a slight increase in the ability of NK cells to respond to target cells bearing the ligands for these receptors. In contrast, NKG2A(+) and CD94(+) NK cells were elevated in acute and chronic HCV infection, but not in resolved infection. Most importantly, in acute infection, lower frequencies of NKp30(+), NKp46(+), CD161(+), and NKG2D(+) NK cells were observed in patients who were subsequently able to clear HCV infection than in those becoming chronically infected. CONCLUSIONS: These data implicate particular populations of NK cells in the early control and clearance of HCV infection.
Authors: O Mandelboim; N Lieberman; M Lev; L Paul; T I Arnon; Y Bushkin; D M Davis; J L Strominger; J W Yewdell; A Porgador Journal: Nature Date: 2001-02-22 Impact factor: 49.962
Authors: Georg M Lauer; Kei Ouchi; Raymond T Chung; Tam N Nguyen; Cheryl L Day; Deborah R Purkis; Markus Reiser; Arthur Y Kim; Michaela Lucas; Paul Klenerman; Bruce D Walker Journal: J Virol Date: 2002-06 Impact factor: 5.103
Authors: N Kawarabayashi; S Seki; K Hatsuse; T Ohkawa; Y Koike; T Aihara; Y Habu; R Nakagawa; K Ami; H Hiraide; H Mochizuki Journal: Hepatology Date: 2000-11 Impact factor: 17.425
Authors: Betty Pham; Karine Piard-Ruster; Richard Silva; Amy Gallo; Carlos O Esquivel; Olivia M Martinez; Sheri M Krams Journal: Pediatr Transplant Date: 2012-03
Authors: Jessica Prince; Alyssa Lundgren; Michael D Stadnisky; William T Nash; Amira Beeber; Stephen D Turner; Michael G Brown Journal: J Immunol Date: 2013-09-25 Impact factor: 5.422
Authors: Tarik Azzi; Anna Lünemann; Anita Murer; Seigo Ueda; Vivien Béziat; Karl-Johan Malmberg; Georg Staubli; Claudine Gysin; Christoph Berger; Christian Münz; Obinna Chijioke; David Nadal Journal: Blood Date: 2014-09-09 Impact factor: 22.113